Literature DB >> 22113733

Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants.

Maya S Salnikova1, Harrison Davis, Christopher Mensch, Lauren Celano, David S Thiriot.   

Abstract

Freezing and thawing of vaccines containing aluminum adjuvants can lead to formation of aggregates and loss in vaccine potency. We sought to understand whether and to what extent the freeze-thaw damage to aluminum adjuvants would differ based on suspension state (flocculation and settlement) at the time of freezing. As flocculation and settlement characteristics of aluminum adjuvants are driven largely by the electrostatic charges on the adjuvant particles, which, in turn, are strongly influenced by the pH of the suspension, we conducted freeze-thaw studies on both Adjuphos and Alhydrogel™ samples at three pH levels (4, 6.5, and 7.2) in buffer solutions with 9% sucrose. Significantly less aggregation occurred in the buffered sucrose solutions at the pH furthest from the aluminum adjuvant point of zero charge during slow freezing at -20°C. The freezing-induced aggregation for the samples with 9% sucrose at each pH was minimal during fast freezing at -70°C and -115°C. Suspensions that were flocculated and settled to a greater extent experienced the most freeze-thaw aggregation, whereas suspensions that were frozen before significant flocculation and settlement occurred showed little or no aggregation. Because pH of formulation can affect flocculation and settling time, it indirectly affects the extent of freeze-thaw aggregation.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113733     DOI: 10.1002/jps.22815

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

2.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

Review 3.  Adjuvant formulations for virus-like particle (VLP) based vaccines.

Authors:  Velasco Cimica; Jose M Galarza
Journal:  Clin Immunol       Date:  2017-08-03       Impact factor: 3.969

4.  Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors:  Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2013-04-10       Impact factor: 5.571

5.  Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components.

Authors:  Robert B D Otto; Karena Burkin; Saba Erum Amir; Dennis T Crane; Barbara Bolgiano
Journal:  Biologicals       Date:  2015-07-17       Impact factor: 1.856

6.  Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.

Authors:  Vishal M Toprani; Neha Sahni; John M Hickey; George A Robertson; C Russell Middaugh; Sangeeta B Joshi; David B Volkin
Journal:  Vaccine       Date:  2017-05-24       Impact factor: 3.641

7.  Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.

Authors:  Juliette Fortpied; Florence Wauters; Christelle Rochart; Philippe Hermand; Bernard Hoet; Nicolas Moniotte; Ivo Vojtek
Journal:  Hum Vaccin Immunother       Date:  2018-02-12       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.